Back to Newsroom
Back to Newsroom

NovaBay Pharmaceuticals' NeutroPhase®: A New Adjunctive Therapy to Manage 'Flesh-Eating' Disease

Monday, 09 December 2013 09:20 AM

Topic:

Dr. John Crew, a wound care specialist at Seton Medical Center, describes first successful procedure that removes toxins from wounds with less invasive debridement and avoids possible amputation 

NEW YORK, NY - December 9, 2013:  CEONews.Tv, an online news service that covers the small cap market for investors (http://ceonews.tv/), announced today that its interview with Dr. John Crew has revealed some important medical news - the first use of adjunctive NeutroPhase® irrigation therapy in conjunction with Negative Pressure Wound Therapy (NPWT) to successfully manage the severely-infected wound in the arm of a patient with life-threatening 'flesh-eating' disease.  

The news was described by Dr. John R. Crew, MD, FACS, vascular surgeon and medical director of the Advanced Wound Care Center, Seton Medical Center in Daly City, California, in an interview on CEONews.Tv with Dr. Crew told interviewer Charles Sample (http://www.ceonews.tv/nby). 

In the interview, Dr. Crew described how ‘flesh-eating disease’ (also known as necrotizing fasciitis or toxic inflammatory cellulitis) kills 20% of its victims - even when they get the standard current treatment. For those who aren’t treated, the mortality rate climbs to 70%. And even many of those who do survive lose arms or legs. 

Dr. Crew explained that now there is a new approach. "We are developing a new way to manage the life-threatening wounds and infections," he said. The key is infusing the wound with a natural substance, hypochlorous acid, that the body uses to fight microbial invaders. Dr. Crew has been working with a California biopharmaceutical company, NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) (http://novabay.com/) that has created a stable version of hypochlorous acid called NeutroPhase®. Dr. Crew has been testing NeutroPhrase as adjunctive therapy to manage  a variety wounds, including those that create flesh-eating disease.  

Dr. Crew described how he used NeutroPhase to treat a patient who recently came into the hospital in toxic shock with flesh-eating disease ravaging her arm. "We were able to instill in the wound the product," he said. The treatment saved the woman's life - and her arm. But there was a medical puzzle, Dr. Crew said. By the time he began to treat the woman, the bacteria that had originally caused the life-threatening infection had already been killed by antibiotics. While hypochlorous acid also kills bacteria, the woman’s rapid recovery suggested that the product was doing something more. 

Dr. Crew said, laboratory work showed that NeutroPhase not only kills bacteria, it also neutralizes the deadly toxins, produced by both bacteria and the body's own immune system, that eat away tissue. "There are many toxins involved in dissolving cellular tissue that is defective," explained Dr. Crew. "This is the normal reaction to rid the body of dying cells." The trouble is that, in flesh-eating disease, these toxins get out of control and chew up healthy tissue as well as dying cells. NeutroPhase neutralizes those out-of-control toxins, the lab analysis showed. "This was very exciting," said Dr. Crew. 

Dr. Crew explained that he is now trying to get the word out to the medical community "to show we have a new way to treat a very serious disease" 

He added that the product is very safe, and could be used to treat all kinds of wounds, not just those caused by flesh-eating disease. "My personal opinion is that it belongs in everyone’s medicine cabinet," he said in the interview. 

About CEONews.Tv: CEONews.Tv is an online market news and mobile news provider that brings investors - Big News For The SmallCap Market!(TM). CEONews.Tv offers platforms that allow CEOs, CFOs, COOs, Presidents and Directors of companies to deliver answers to the questions that investors would like asked. Through these mediums Executives share their insights, accomplishments, current projects, daily challenges they face and the future goals and aspirations they have for the companies that they lead. For further information please visit http://www.ceonews.tv/. To have Your Company Interviewed please send an email request to: [email protected] or call 765.CEO.NEWS (236-6397).

Forward Looking Statements: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions relating to NovaBay's future business prospects and clinical trials. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. In addition, description of anyone's past success, either financial or strategic, is not a guarantee of future success. This news release speaks as of the date first set forth above and neither CEONews.Tv or the interviewed company assumes any responsibility to update the information included herein for events occurring after the date hereof.

CONTACT:

Charles Sample II
765.CEO.NEWS (236-6397)
[email protected]
[email protected]

Topic:
Back to newsroom
Back to Newsroom
Share by: